About The Speaker
Victor Greiff
UNIVERSITY OF OSLO, ASSOCIATE PROFESSOR FOR SYSTEMS IMMUNOLOGY Victor Greiff is an Associate Professor for Systems Immunology at the University of Oslo since 2018. His group develops machine learning, computational and experimental tools for immune-repertoire-based in silico immunodiagnostics and immunotherapeutics discovery and design. He is the president of the Norwegian Society for Immunology and the current Chair of the AIRR Community. Victor received his PhD in Systems Immunology from Humboldt University (Germany, 2012) and performed his postdoctoral training at ETH Zürich (Switzerland, 2013-17).
Victor Greiff
UNIVERSITY OF OSLO, ASSOCIATE PROFESSOR FOR SYSTEMS IMMUNOLOGY
Victor Greiff is an Associate Professor for Systems Immunology at the University of Oslo since 2018. His group develops machine learning, computational and experimental tools for immune-repertoire-based in silico immunodiagnostics and immunotherapeutics discovery and design. He is the president of the Norwegian Society for Immunology and the current Chair of the AIRR Community. Victor received his PhD in Systems Immunology from Humboldt University (Germany, 2012) and performed his postdoctoral training at ETH Zürich (Switzerland, 2013-17).
Targeting FcRn for the therapy of autoimmune disease
The central role of FcRn in regulating immunoglobulin G (IgG) persistence and transport provides opportunities for targeting this receptor in multiple different diagnostic and therapeutic situations. The engineering of IgGs with higher affinity for FcRn can be used to produce antibodies with longer in vivo half-lives, but only if the low affinity of the IgG-FcRninteraction at near neutral pH is retained. Conversely, an engineered IgG or Fc fragmentwith increased affinity for FcRn at both acidic and near neutral pH acts as a potent inhibitor of FcRn. Consequently, such an antibody (‘Abdeg’, for antibody that enhancesIgG degradation) can lower the levels of endogenous IgG and has led to the FcRn antagonist, efgartigimod, that has been developed by argenx and recently approved for the treatment of myasthenia gravis. Our recent work has also resulted in the generation of engineered Fc-fusions that selectively clear antigen-specific antibodies (‘Seldegs’, for selective degradation). Developments related to the modulation of the dynamic behavior of IgG in the bodywill be presented.